CD19 CLIP CAR-NK / TiCARos - LARVOL DELTA

Cartherics enters into Collaborative Research Agreement with TiCARos (Cartherics Press Release) - "Cartherics Pty Ltd...is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd...to assess its proprietary CLIP-CAR technology in Cartherics’ induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells...TiCARos is developing novel chimeric antigen receptor (CAR)-T cell products for the treatment of solid and blood cancers incorporating its CLIP-CAR (Clamping-based Immunological Synapse Potentiating CAR) approach. The CLIP component stabilises the immune synapse between immune cells and target tumour cells by modifying the CAR structure, thereby improving the contact between CAR-T cells and tumour cells, resulting in enhanced efficacy in vitro and in vivo models....TiCARos will be assessing CD19 as its tumour target. Each party retains the right to develop products that target its nominated tumour antigen."

Licensing / partnership • Oncology